Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update
10 nov. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual...
Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance
07 nov. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial
20 oct. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting
17 oct. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
04 oct. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
21 sept. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
06 sept. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update
15 août 2022 07h00 HE
|
Talaris Therapeutics, Inc.
All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were...
Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update
30 juin 2022 07h00 HE
|
Talaris Therapeutics, Inc.
All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001...
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022
07 juin 2022 16h01 HE
|
Talaris Therapeutics, Inc.
Real-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer cardiometabolic complications than patients on...